It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
No imaging modality can be used to evaluate Fontan-associated liver disease (FALD). We retrospectively reviewed hepatic gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid-enhanced magnetic resonance imaging (EOB-MRI) characteristics of patients within 1 year post-Fontan procedure, and we evaluated the association between hepatic imaging abnormalities and clinical parameters, including follow-up cardiac catheterization and laboratory test findings. The EOB-MR images were graded, based on the extent of the decreased enhancement, as “normal” (Grade 1), “segmental” (Grade 2), “regional” (Grade 3), and “diffuse” (Grade 4). We enrolled 37 patients (mean age, 3.5 ± 1.0 years): 9 patients had Grade 1 or 2; 14 patients, Grade 3; and 14 patients, Grade 4. EOB-MRI revealed characteristic reticular or mosaic patterns of diminished enhancement (i.e. “frog spawn” appearance). Ultrasonography did not detect diminished enhancement or “frog spawn” appearance. A trend existed toward increased grade severity in imaging with increased central venous pressure, pulmonary vascular resistance, and gamma-glutamyltransferase levels. Noninvasive EOB-MRI revealed the characteristic pattern of diminished enhancement, which was correlated with certain clinical parameters indicative of Fontan physiology and liver dysfunction. Early-stage FALD may occur soon after the Fontan procedure and is associated with increased pressure in the inferior vena cava and hepatic veins.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details

1 Gunma Children’s Medical Center, Department of Cardiology, Gunma, Japan (GRID:grid.410822.d) (ISNI:0000 0004 0595 1091); Gunma University Graduate School of Medicine, Department of Pediatrics, Gunma, Japan (GRID:grid.256642.1) (ISNI:0000 0000 9269 4097)
2 Gunma Children’s Medical Center, Department of Cardiology, Gunma, Japan (GRID:grid.410822.d) (ISNI:0000 0004 0595 1091)
3 Gunma Children’s Medical Center, Department of Radiology, Gunma, Japan (GRID:grid.410822.d) (ISNI:0000 0004 0595 1091)
4 Gunma Children’s Medical Center, Department of Cardiovascular Surgery, Gunma, Japan (GRID:grid.410822.d) (ISNI:0000 0004 0595 1091)
5 Gunma University Graduate School of Medicine, Department of Pediatrics, Gunma, Japan (GRID:grid.256642.1) (ISNI:0000 0000 9269 4097)